InMode Ltd. (INMD) is a leading provider of medical technologies that harness both radio-frequency and laser-based energies for the purpose of aesthetic and dermatological procedures. The company, whose key foundation is rooted in years of development and research, was established in 2008 and has headquarters based in Yokneam Illit, Israel.
InMode’s technologies are globally recognized with their cutting-edge applications in treatments such as body contouring, skin rejuvenation, wrinkle reduction, hair removal, and more. Remarkably, the company takes pride in successfully offering minimally invasive and minimal downtime solutions, which makes their services key in a world where aesthetic procedures are becoming more popular and patient comfort is a priority.
The company has revolutionized its sector with advancements in technology such as their proprietary EmbraceRF technology. This technology used in aesthetic medical procedures combines radio frequency energy with precision to offer an array of procedures with minimal scarring and incredibly speedy recovery. The company endeavors to provide clinically proven medical aesthetic solutions that deliver an effective, yet safe and non-invasive experience.
InMode’s commitment to clinical excellence and technological innovation have fostered a strong financial performance, with its shares traded on the NASDAQ Global Select Market under INMD. The company's strategic vision, focused on developing and innovating new technologies, has resulted in strong customer loyalty and increasing revenues.
Moreover, InMode displays significant corporate social responsibility activity. It has leveraged its technology and knowledge to help those less fortunate, which is showcased in projects where its technology has been applied to alleviate the physical suffering of war victims.
In health safety, the company goes an extra mile. Remaining loyal to the cause of ensuring the safety of the end-users of their technologies, its products are medical-grade, meticulously engineered, and certified by relevant regulatory boards for utmost safety and reliability.
In the present, InMode continues to grow and expand new frontiers in medical aesthetics, driven by a passion to deliver better, more efficient, patient-friendly methods. Its hardworking team of scientists, engineers, and clinical professionals are committed to careful research and design to meet the ever-evolving demands and standards of the aesthetic technology industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article provides a real-time analysis of Inmode Ltd. (NASDAQ: INMD) stock movement, highlighting weak near-term sentiment and potential bearish positioning. It details support and resistance levels, and offers three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and key support/resistance signals.
InMode (INMD) shares fell in premarket trading after an unsolicited takeover offer from M.N. Business Strategy, a group backed by InMode's CEO, expired. The company had previously disclosed the bid.
InMode Ltd. (INMD) appears reasonably valued at 11.4x forward earnings, but faces significant challenges including flat revenue and earnings growth, margin compression, and geopolitical risks. Despite buyout offers and insider buying, Wall Street remains largely pessimistic due to operational headwinds and a lack of management transparency. The stock's limited upside potential is further constrained by its exposure to discretionary products and current macroeconomic uncertainties.
Wellington Management Group LLP has invested $1.25 million in InMode Ltd. (NASDAQ:INMD), acquiring 85,751 shares, which represents about 0.15% of the company. Other institutional investors like Goldman Sachs and Marshall Wace also significantly increased their holdings in InMode. The company recently reported quarterly EPS of $0.35 and revenue of $95.59 million, both meeting or slightly exceeding analyst expectations, and maintains a consensus "Hold" rating from analysts with a target price of $16.00.
InMode Ltd. (NASDAQ:INMD) has received an average "Hold" rating from brokerages, with six out of eight analysts recommending a hold, one a sell, and one a buy. The average 12-month price target is $16.00, slightly above its current share price of $14.79. The company recently met earnings expectations with $0.35 EPS and reported revenue of $95.59 million, surpassing estimates.
Bank of America Corp DE significantly reduced its stake in InMode Ltd. (NASDAQ:INMD) by selling 236,577 shares, leaving them with 50,508 shares valued at $691,000. Despite this, other institutional investors like Steel Partners Holdings, Millennium Management, and Goldman Sachs increased their positions. InMode reported Q1 EPS of $0.35, meeting estimates, and revenue of $95.59 million, exceeding forecasts, while analysts maintain a consensus "Hold" rating with an average price target of $16.00.
InMode (NASDAQ:INMD) stock recently crossed above its 200-day moving average, trading at $15.03 with a 200-day average of $14.26. The company reported quarterly EPS of $0.35, matching estimates, and revenue of $95.59 million, exceeding expectations. Analyst sentiment for InMode remains cautious, with a consensus "Hold" rating and a price target of $16.00.